Trump Signs $867B Bipartisan Farm Bill with Welfare Reform Work Requirements

President Donald Trump signed into law the $867 billion farm bill Thursday, which includes welfare reform requiring able-bodied adults without children to work or look for work.

“In addition to signing this critical legislation, today I am directing my administration to take immediate action on welfare reform. Thanks to our thriving economy, we have already lifted more than 4.6 million Americans off the food stamp roll since the election, and more work remains to be done,” Trump said.

Trump called the bill “a bipartisan success.” It doubles the number of farmers who can borrow to expand and improve their farms. It also expands rural broadband, provides more resources to fight the opioid crisis, and opens new markets for U.S. agriculture overseas.

“Millions of able-bodied, working-age adults continue to collect food stamps without working or even looking for work. Our goal is to move these Americans from dependence to independence, and into a good-paying job and rewarding career. Therefore, I have directed Secretary Perdue to use his authority under the law to close work requirement loopholes in the food stamp program,” the president said.

“Under this new rule, able-bodied adults without dependents will have to work, or look for work, in order to receive their food stamps. Today’s action will help Americans transition from welfare to gainful employment, strengthening families and uplifting communities, and that was a difficult thing to get done, but the farmers wanted it done,” Trump said.

“We all wanted it done, and I think, in the end, it's going to make a lot of people very happy. It's called ‘work rules,’ and Sonny is able, under this bill, to implement them through regulation,” he added.

A black conservative group, Project 21, applauded the welfare reform regulation, saying it is consistent with a recommendation found in their "Blueprint for a Better Deal for Black America."

"People should not be able to become professional entitlement beneficiaries – especially during times of low unemployment. President Trump and the U.S. Department of Agriculture should be commended for wanting to make sure our tax dollars are spent wisely," said Project 21 member Emery McClendon.

"Our government has programs in place to help citizens who fall on hard times. Programs such as SNAP are intended to be temporary. It would greatly enhance those who are enrolled in these programs as well as the communities in which they live if there were work or training requirements linked to continued assistance," McClendon added.

“To ‘reinforce the… intent’ of the Food and Nutrition Act of 2008 and meet the goals of President Donald Trump's April 2018 executive order on welfare reform, the U.S. Department of Agriculture (USDA) announced a proposed rule today to limit state waivers on SNAP eligibility,” the group said.

“While SNAP requires able-bodied individuals to work 80 hours a month or participate in a job training program to maintain eligibility for benefits, states have been allowed to obtain waivers for extended periods based on local unemployment rates. The proposed rule seeks to curtail ‘widespread use’ of waivers that the Trump Administration believes were meant for "temporary relief… in an economic downturn."

The proposed regulation applies to adults 18-48, who don’t have dependents, and are able-bodied. Pregnant women and disabled persons are exempt from work requirements.

"If you are able-bodied, government assistance should be a safety net and not a hammock. As someone who was once on food stamps, I know it is necessary. And the exact order addresses the able-bodied without dependents. There is no excuse for those on welfare not trying to help their community or help themselves," said Project 21 member Marie Fischer-Wyrick.

"When I lost a job after 20 years in the workforce, I was on assistance with two dependents. I not only looked for work while on assistance, but I took certification courses to find a better position. I only needed assistance for short time because I knew it was not a way of life for myself or my children," she added.

SOURCE 

*******************************

There are important deregulation efforts afoot that will help lower prescription-drug prices 

Here’s a bit of good news as we head into the Christmas season. Last week, the Food and Drug Administration withdrew a rule that would have put patients’ health at risk and made it more expensive to buy medicine.

As a Wall Street Journal editorial recently stated, “[The] rule proposed by the Obama Administration in 2013 allowed generic drug makers to tailor their own safety labels, which historically must be identical to the branded product. The rule’s biggest supporter was the plaintiffs bar, which figured this would open up more opportunities for lawsuits for failing to warn consumers about all and sundry risks. The practical effect would be to make drug labels even more incomprehensible than they are now, varying among products that are chemically identical.”

Not only would patients face possible health risks due to the confusion over labels, but generic drug prices would also have increased nationwide more than $4 billion. And this cost would likely increase once litigation costs were passed onto consumers.

Again, this is what happens when government meddles with the free market.

President Donald Trump vowed during his 2016 presidential campaign to make patients’ access to medicine more affordable. Since then, he’s been a consistent critic of Big Pharma, but his record is mixed.

On one hand, Trump’s goal is to make prescription drugs more affordable. The Journal reports, “The FDA has over 20 months of the Trump Administration approved an astounding 1,617 generic drugs, which are identical to branded versions but sold at commodity prices after patents expire. That works out to 81 a month on average — an 17% increase over the preceding 20 months. The Council of Economic Advisers in October tried to tally the savings from new entrants: $26 billion.”

On the other hand, Trump’s intervention in the free market is backfiring, as some companies have raised their prices in response to discounted drugs in an effort to retain profits.

According to The Resurgent, Pfizer will “raise the prices of 41 drugs in January, amid escalating Trump administration efforts to lower prescription drug prices and months after Trump’s intervention forced the largest U.S. drugmaker to postpone planned cost increases.”

There’s plenty of blame to go around on this issue. Democrats want to set up an agency that would have broad power to investigate and punish drug companies that don’t fall in line with their goal of government-run health care. Think “Consumer Financial Protection Bureau” for prescription drugs, and you’ll understand why it’s a bad idea. Meanwhile, President Trump wants to impose European-style price controls on Big Pharma.

While the Trump administration may be toying around too much with the free market, Democrat Sen. Elizabeth Warren is going even further by proposing more government intervention masked as a free-market solution.

The Daily Signal reports, “The Affordable Drug Manufacturing Act seeks to address the increasing prices of prescription drugs by injecting competition into the marketplace, consequently lowering the cost of mass-produced generic drugs. The bill would create the Office of Drug Manufacturing, which would be housed within the Department of Health and Human Services.” Additionally, “The Office of Drug Manufacturing would be tasked with producing drugs in cases where the market has been deemed to have failed.” Warren claims that the program would be “self-sustaining,” but that’s a promise that might be harder to keep than Barack Obama’s notorious “you can keep your doctor” whopper.

In both cases, the free market loses and Americans end up paying more for health care that’s increasingly controlled by government bureaucrats. In the end, the only system that really works is to leave the markets alone rather than embracing Europe’s path to government health care.

As The Wall Street Journal reminds us, “For all the talk of wondrous European health-care systems, the American generics system is the envy of the world. Nine in 10 prescriptions in the U.S. are cheaper generics, which saved $265 billion last year. Compare that with 70% in Canada and less than half in many European countries. The U.S. pays big for breakthroughs but eventually prices fall as competition arrives. Europe enjoys less price discipline.”

As always, it’s amazing what the free market can do when the government gets out of the way.

SOURCE 

*************************************

The Food and Drug Administration’s Invisible Victims

Among the U.S. Food and Drug Administration’s responsibilities are approval and regulation of pharmaceutical drugs. In short, its responsibility is to ensure the safety and effectiveness of drugs. In the performance of this task, agency officials can make two types of errors—statistically known as the type I error and type II error.

With respect to the Food and Drug Administration, a type I error is the rejection or delayed approval of a drug that is safe and effective—erring on the side of over-caution—and a type II error is the approval of a drug that has unanticipated dangerous side effects, or erring on the side of under-caution.

Let’s examine the incentives of Food and Drug Administration officials.

If agency officials err on the side of under-caution and approve a drug that has unanticipated dangerous side effects, the victims of their mistake will be highly visible. There may be congressional hearings, embarrassment to the agency, and officials fired.

It’s an entirely different story if agency officials err on the side of over-caution and either disapprove or delay the approval of a drug that is both safe and effective.

In that case, the victims will be invisible. They will have no idea that their suffering could have been eliminated, or in the case of death, their loved ones will have no idea why they died. Their suffering and/or death will be chalked up to the state of medicine rather than the status of a Food and Drug Administration drug application. Their doctor will simply tell them there’s nothing more that can be done to help them. The Food and Drug Administration officials go scot-free.

Let’s look at some of the history of the Food and Drug Administration’s erring on the side of over-caution.

Beta blockers reduce the risk of secondary heart attacks and were widely used in Europe during the mid-1970s. The Food and Drug Administration imposed a moratorium on approvals of beta blockers in the U.S. because of their carcinogenicity in animals.

Finally, in 1981, the Food and Drug Administration approved the first such drug, boasting that it might save up to 17,000 lives per year. That means that as many as 100,000 people died from secondary heart attacks waiting for Food and Drug Administration approval.

Those people are in the “invisible graveyard,” a term to describe people who would have lived but died because the cure that could have saved them was bottled up in the Food and Drug Administration’s regulatory process.

Today, the Phoenix-based Goldwater Institute is leading the battle to bring some sanity and compassion to the drug approval process. It recently published a paper by Mark Flatten, titled “Studied to Death: FDA Overcaution Brings Deadly Consequences.” Flatten examined the Food and Drug Administration’s approval process and made some important recommendations.

Flatten criticized some Food and Drug Administration practices, saying, “Instead of having to prove a new treatment is safe for its intended use, the FDA now reviews drugs based on how they might be used by doctors to treat individual patients, effectively substituting the judgment of agency regulators for that of practicing medical professionals.” He added:

Instead of proving a drug achieves the medically beneficial results that its makers claim, the FDA requires proof the new treatment will improve long-term outcomes. So it is no longer enough, for instance, to prove a new drug will reduce blood glucose levels for diabetics. Drugmakers must show, somehow, that this will make patients live longer.

One Goldwater Institute suggestion is to allow drugs approved in certain other countries, such as Canada and the European Union, to receive nearly automatic U.S. approval. After all, those countries have drug regulatory structures similar to that in the U.S. Why should treatments approved in those countries not be available here?

The Goldwater Institute is also calling for a bill to restore free speech in medicine. It thinks Congress should allow drug manufacturers to provide information about “off-label use.” This is a common practice in which doctors prescribe Food and Drug Administration-approved drugs to treat conditions other than those the agency originally approved them for after new beneficial uses arise.

Strong evidence of the agency’s over-caution bias comes in the 1974 words of then-Food and Drug Administration Commissioner Alexander M. Schmidt: “In all of FDA’s history, I am unable to find a single instance where a congressional committee investigated the failure of FDA to approve a new drug.”

SOURCE 

***********************************

Asylum-Seekers to be Returned to Mexico Pending Decision; Pompeo Foresees ‘Historic Drop in Illegal Immigration’

Secretary of State Mike Pompeo on Thursday predicted that a new plan to send illegal aliens back to Mexico to await the outcome of U.S. asylum applications will result in “a truly historic drop in illegal immigration,” since the prospect of being able to disappear into the U.S. will no longer be an incentive.

“The idea of ‘catch and release’ will be replaced with ‘catch and return,’” Pompeo told Laura Ingraham on the final episode of her long-running radio show, after Homeland Security Secretary Kirstjen Nielsen announced the policy, which is to be implemented with immediate effect.   

Aliens crossing the southern border illegally, or arriving at a border port of entry without proper documentation and applying for asylum will be given a court date and “notice to appear” before being returned to Mexico.

The Mexican government has agreed they may stay there on the basis of a humanitarian visa, apply for paid employment, get access to immigration attorneys, and be able to travel to the U.S. for their court hearings.

According to the DHS, federal immigration judges rule against nine out of ten asylum claims, but by the time unsuccessful applicants are ordered to be removed from the country, “many have vanished.”

Pompeo acknowledged the likelihood of lawsuits challenging the decision, but said the administration was confident the plan was legal, as it’s based on long existing law.

Section 235 of the Immigration and Naturalization Act of 1952 states that when an alien arrives on land from a foreign territory contiguous to the United States with a claim for asylum to be considered, “the Attorney General may return the alien to that territory pending a proceeding.”

“We remain convinced that this is a power that the president was granted by Congress to execute exactly the way we have,” Pompeo told Ingraham. “We’ve had lots of thought and legal review of this. We are confident that we are on firm ground.”

In her statement, Nielsen said, “Aliens trying to game the system to get into our country illegally will no longer be able to disappear into the United States, where many skip their court dates. Instead, they will wait for an immigration court decision while they are in Mexico.”

She listed expected benefits arising from the policy, including:

--Declining illegal immigration and fewer false asylum claims

--Greater attention to be given to genuine asylum-seekers’
applications, since incentives for “fraudsters” will be gone

--The freeing-up of resources and personnel to focus on protecting U.S. territory and reducing an asylum backlog of more than 786,000 pending cases

--Protection for vulnerable individuals as they await determination of their cases in Mexico.

In his radio interview, Pompeo offered another purported benefit – that migrants will not face the risks entailed in making the journey from their home countries, through Mexico, to the U.S. border.

Mexico’s foreign ministry confirmed that it would respond to the policy by authorizing the temporary entrance of migrants awaiting asylum applications in the U.S.

“They will be entitled to equal treatment with no discrimination whatsoever and due respect will be paid to their human rights,” the ministry said in a statement. “They will also have the opportunity to apply for a work permit for paid employment, which will allow them to meet their basic needs.”

Those who have received a notice to appear before an immigration court in the U.S. will be allowed access to legal and information services.

The ministry stressed that its actions, and those taken by the U.S., do not constitute a “safe third country” arrangement – whereby the migrants concerned would be required to apply for asylum in Mexico.

Although they may apply for asylum in Mexico, the arrangement is intended to facilitate their applications in the U.S.

White House press secretary Sarah Sanders praised the Mexican government, saying on Twitter it was “now doing more to solve our illegal immigration problem than the Democrats.”

SOURCE 

**************************************

For more blog postings from me, see  TONGUE-TIED, EDUCATION WATCH INTERNATIONAL, GREENIE WATCH,  POLITICAL CORRECTNESS WATCH, AUSTRALIAN POLITICS, and Paralipomena (Occasionally updated),  a Coral reef compendium and an IQ compendium. (Both updated as news items come in).  GUN WATCH is now mainly put together by Dean Weingarten. I also put up occasional updates on my Personal blog and each day I gather together my most substantial current writings on THE PSYCHOLOGIST.

Email me  here (Hotmail address). My Home Pages are here (Academic) or  here (Pictorial) or  here  (Personal)

**************************